Bicycle Therapeutics (BCYC) Construction in Progress (2022 - 2023)
Bicycle Therapeutics posted quarterly Construction in Progress of $400000.0 for Q2 2023, down 82.61% on a QoQ basis from $2.3 million in Q4 2022.
Bicycle Therapeutics (BCYC) has 2 years of Construction in Progress data on file, last reported at $400000.0 in Q2 2023.
- For the quarter ending Q2 2023, Construction in Progress changed N/A year-over-year to $400000.0; the trailing twelve-month figure through Jun 2023 stood at $400000.0 (changed N/A YoY), and the FY2022 full-year result was $2.3 million, changed N/A from the prior year.
- Construction in Progress for Q2 2023 stood at $400000.0, down from $2.3 million in the prior quarter.
- Across five years, Construction in Progress topped out at $2.3 million in Q4 2022 and bottomed at $400000.0 in Q2 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Bicycle Therapeutics | 326.82 Mn | 326.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 400,000.00 |
| Dec 31, 2022 | 2.30 Mn |